The NAD+ Question: What the Science Actually Shows About Longevity’s Most Hyped Supplement

The wellness industry is selling NAD+ pills, patches, and IV drips as keys to reversing biological aging. On May 11, 2026, NPR asked what the evidence actually shows. We went deeper.

Presented By Our Partners

Walk into any longevity clinic in 2026 and you will likely be offered a NAD+ infusion. Search the top supplement retailers and you will find hundreds of products promising to “restore youthful NAD+ levels,” slow cellular aging, boost mitochondrial energy, and protect your DNA. Wellness influencers and anti-aging entrepreneurs claim the molecule is the closest thing to a biological reset button that science has yet discovered, and the supplement industry has responded accordingly, with the global NAD+ precursor market now valued in the billions.

On May 11, 2026, NPR published a major investigative piece posing a simple and necessary question: what does the actual research show? The story found a wide chasm between what marketers claim and what peer-reviewed science has established. Researchers quoted in the piece noted plainly that “the health benefits of augmenting NAD+ are yet to be established in large human studies.”

This article goes deeper. We trace the biology of NAD+ from foundational science to the latest clinical trials, examine why the preclinical evidence generated such excitement, and assess honestly what has and has not translated to humans. The picture that emerges is more nuanced than either the supplement industry or its critics tend to acknowledge.

The Biology: Why NAD+ Occupies a Central Role in Aging Research

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every living cell. It plays an indispensable role in cellular energy metabolism, acting as an electron carrier in the mitochondrial processes that convert food into ATP, the body’s primary energy currency. But NAD+’s relevance to aging goes beyond energy production.

Two families of enzymes that depend on NAD+ have made the molecule central to longevity science. Sirtuins, often called “longevity proteins,” are a class of seven enzymes that regulate a wide range of biological processes including DNA repair, inflammation response, mitochondrial biogenesis, and epigenetic maintenance. They are NAD-dependent: without adequate NAD+ levels, sirtuins cannot function effectively. PARP enzymes, a second NAD-consuming family, are the cell’s primary DNA damage responders, deploying rapidly whenever the genome sustains injury. Under conditions of chronic stress or disease, PARP activity can consume NAD+ faster than cells replenish it.

The problem, and the foundation of the entire longevity supplement argument, is that NAD+ levels decline substantially with age. Studies in rodents and humans consistently show that by middle age, tissue NAD+ levels have fallen by 30 to 50 percent compared to young adulthood. Researchers at Harvard Medical School, Washington University in St. Louis, and the University of New South Wales have each documented this decline and proposed that it contributes to the metabolic dysfunction, mitochondrial deterioration, and impaired DNA repair that characterize biological aging.

David Sinclair, Professor of Genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for Biology of Aging Research, has been one of the most prominent voices in NAD+ research. His lab was among the first to identify that NAD+ biosynthesis regulates lifespan in yeast and that sirtuins mediate the longevity effects of caloric restriction in mammals. Sinclair’s work, and subsequent research from labs around the world, established a biological rationale for asking whether raising NAD+ levels in aging animals, and eventually humans, could slow or reverse aspects of cellular decline.

The Preclinical Evidence: What Mouse Studies Showed

Between 2013 and 2023, a wave of mouse studies generated genuine excitement in the longevity research community. Animals given NAD+ precursor supplements showed measurable improvements across a range of aging-related outcomes.

In a landmark 2013 Cell paper, researchers at Harvard and the National Institute on Aging showed that one week of NAD+ precursor supplementation in aging mice produced muscle tissue that was biochemically indistinguishable from much younger animals. The treated mice showed improvements in mitochondrial function, reduced markers of inflammation, and restored levels of sirtuin activity. A 2016 study published in Science found that NMN supplementation improved vascular function, endurance, and energy metabolism in aging mice. Studies in mouse models of Alzheimer’s disease, heart failure, kidney disease, and metabolic syndrome all pointed in a consistent direction: raising cellular NAD+ appeared to be broadly protective.

These results were not trivial or marginal. In several studies, the effects were substantial enough that researchers began describing NAD+ precursors as potential interventions not just for specific diseases but for aging itself. The pathway from preclinical signal to human investigation seemed well justified, and by the mid-2010s, clinical trials in humans were underway.

The Delivery Problem: Why You Cannot Simply Take NAD+

Before examining what the human evidence shows, it is worth understanding a critical biochemical challenge that shapes the entire supplement discussion. NAD+ itself cannot be efficiently delivered by swallowing a pill. When taken orally, the molecule is largely degraded in the gut before reaching systemic circulation. This is why the NAD+ supplement market pivoted to precursors: molecules the body can absorb and then convert into NAD+ through natural biosynthesis pathways.

The two dominant precursors are nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Both are naturally present in small quantities in foods including milk, edamame, broccoli, and avocado. At supplemental doses, both have been shown in human trials to reliably raise circulating NAD+ levels in the blood, typically doubling them after two weeks of consistent supplementation at doses around 1,000 mg per day.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

A January 2026 randomized, double-blind, placebo-controlled trial with 65 healthy adults found that both NR and NMN produced roughly equivalent increases in blood NAD+ levels, while plain nicotinamide (Nam) did not produce a sustained increase. The study also revealed an interesting mechanism: gut bacteria appear to convert NMN and NR into nicotinic acid (NA), a potent NAD+ precursor in its own right, suggesting that some of the benefit may be mediated through the gut microbiome rather than through direct absorption of the precursor molecule.

A newer form, reduced NMN (NMNH), showed even more pronounced effects in a first-of-its-kind 90-day human trial published in early 2026, with participants achieving roughly triple the NAD+ increase seen with standard NMN at equivalent doses. However, those results remain unpublished in a peer-reviewed journal and were reported primarily by the sponsoring company, a limitation that warrants caution.

What about IV infusions, the premium offering at longevity clinics charging $200 to $500 per session? Intravenous administration does bypass the gut absorption problem and delivers NAD+ directly to the bloodstream. Anecdotal reports from clinic customers frequently describe a notable increase in energy and mental clarity during or immediately after infusions. What those reports cannot establish, and what no rigorous trial has yet demonstrated, is whether those subjective experiences translate into measurable improvements in cellular health, organ function, or long-term aging outcomes.

Human Clinical Trials: The Evidence Gap That Matters

The honest assessment of the human clinical trial literature on NAD+ precursors, as of May 2026, is this: supplementation reliably raises blood NAD+ levels, but functional improvements in the outcomes that actually matter for health and longevity have been inconsistent, modest, or absent.

A 2025 systematic review published in PubMed, following PRISMA guidelines, examined the accumulated human trial data on NR and NMN. The authors concluded that both compounds “demonstrated biochemical target engagement” and were generally well tolerated, but that “effects on functional, metabolic, vascular, and other healthspan-relevant outcomes were heterogeneous and often null or endpoint-specific.”

On the specific question of muscle function, one of the outcomes most relevant to aging, clinical trials of both NMN and NR have largely failed to show significant improvements in muscle strength, endurance, or physical performance beyond what placebo achieves. A February 2026 randomized trial in college athletes found NMN alone did not improve exercise performance, though a combination with PQQ showed some benefit.

Cognitive outcomes have been similarly mixed. A 2025 trial published in Alzheimer’s and Dementia: Translational Research examined oral NR supplementation in older adults with subjective cognitive decline and mild cognitive impairment. Results showed some improvements in select biomarkers associated with neurodegeneration, but robust improvements in actual cognitive function tests were not consistently demonstrated. A Lancet-published randomized trial examining NR for long-COVID cognitive symptoms found no significant difference between intervention and placebo on the primary outcomes, though exploratory analyses suggested some benefit in executive function and fatigue, a finding that requires replication before drawing conclusions.

The cardiovascular and metabolic picture is equally mixed. Some small trials have shown modest improvements in blood pressure, insulin sensitivity, or lipid profiles, but effect sizes are generally small and results do not consistently replicate across study populations.

Perhaps most importantly, no human trial to date has demonstrated that NAD+ precursor supplementation extends lifespan or reduces the incidence of any specific age-related disease. That is a high bar, requiring large populations and long follow-up times that no trial has yet achieved. It does not mean the effects are absent, but it means the evidence for the most important claimed benefit remains absent.

Safety Profile: What We Know and What We Do Not

On safety, the picture is more reassuring. Short-term use of NR and NMN at doses up to 1,000 mg per day appears to be well tolerated in adults, with no serious adverse events reported in completed trials to date. Common side effects, when reported, are mild and include nausea and digestive discomfort, typically resolving with lower doses or food co-administration.

One area of legitimate scientific caution involves cancer biology. Some preclinical studies have raised the question of whether chronically elevated NAD+ levels could theoretically support the energy demands of tumor cells, given that NAD+ is central to cellular metabolism. This concern has not materialized in human trial data, but it remains a reason why researchers emphasize that multi-year safety trials are needed before long-term supplementation can be confidently recommended, particularly for individuals with a personal or family history of cancer.

A practical problem flagged in the NPR investigation involves supplement quality. Independent testing of products on the market shows considerable variability. What is printed on a label does not always match what is in the capsule, a problem endemic to the broader supplement industry that is not unique to NAD+ precursors but is particularly relevant when consumers are spending $50 to $150 per month based on specific dosing assumptions.

The Foundational Path: What Reliably Raises NAD+ Without a Supplement

An underreported finding in the NAD+ literature is that several foundational lifestyle practices reliably increase cellular NAD+ levels through natural mechanisms, often producing effects comparable to or exceeding what supplementation achieves in trials.

Exercise is the most potent known inducer of NAD+ biosynthesis. Resistance training and aerobic exercise both upregulate the NAMPT enzyme, the rate-limiting step in the primary NAD+ synthesis pathway. Studies using muscle biopsies have shown that regular exercisers maintain substantially higher muscle NAD+ levels than sedentary individuals of the same age. Time-restricted eating and caloric restriction, both of which activate AMPK and sirtuin pathways, also support NAD+ metabolism. Even adequate sleep appears to matter, with sleep deprivation shown in preclinical models to impair NAD+ biosynthesis and accelerate sirtuin inactivation.

This does not mean supplements are useless, but it does mean that a person spending $150 per month on NMN while sleeping five hours a night and sitting most of the day may be getting far less benefit than someone who prioritizes foundational lifestyle practices at no cost.

Where the Research Is Heading

The field is not standing still. Several large-scale trials are now underway or in preparation that should provide more definitive answers within the next three to five years.

The Sinclair lab at Harvard has ongoing programs to develop novel NAD+-boosting molecules and test them in aging and age-related disease models. Multiple academic centers have registered trials on ClinicalTrials.gov examining NAD+ precursors for cardiovascular aging, neurodegeneration, metabolic disease, and cancer survivorship outcomes. The National Institute on Aging has funded several of these investigations through its Interventions Testing Program, which uses standardized protocols across multiple sites to reduce the replication problems that have plagued smaller single-center trials.

One particularly promising emerging direction involves targeting the NAMPT enzyme directly, rather than flooding the system with precursors. Researchers believe that upregulating the body’s own NAD+ production machinery, rather than providing exogenous substrate, may produce more physiologically appropriate and sustained increases without the ceiling effects seen with oral precursor supplementation.

The NMNH research is also worth watching. If the tripled NAD+ levels seen in the 2026 pilot trial replicate in a peer-reviewed, placebo-controlled study, it would represent a meaningful advance in delivery efficiency. Whether higher blood NAD+ translates into improved tissue NAD+ in organs like the brain and heart, which are harder to measure than blood, remains an open and important question.

What This Means for You

The honest answer to the NAD+ question is: the biology is compelling, the preclinical evidence is impressive, and the human data shows that supplementation works as a biochemical intervention in raising NAD+ levels. What has not yet been demonstrated in rigorous human trials is that this biochemical change produces meaningful improvements in the health outcomes that matter most: muscle function, cognitive performance, cardiovascular health, or longevity.

That does not mean NAD+ supplementation is worthless. It may well prove to be a genuine longevity tool as larger and longer trials accumulate. The biological rationale is among the strongest in the supplement space. But the current evidence does not justify the confident anti-aging claims made by many supplement companies and wellness influencers, nor does it support the premium pricing of IV infusion packages that lack any clinical validation of superiority over oral precursors.

If you are interested in supporting NAD+ biology right now, the evidence-based prioritization looks like this: exercise consistently (particularly a combination of resistance training and cardiovascular work), maintain a sleep-first recovery strategy, consider time-restricted eating if metabolic health is a concern, and eat a whole-food diet that includes NAD+ precursor-containing foods. If you choose to add an NR or NMN supplement on top of these foundations, current evidence suggests it is safe and will measurably raise your blood NAD+ levels. Whether it will make you healthier or longer-lived is a question that science is still working to answer.

The supplement market will not wait for that answer. The rest of us probably should.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.